Ambrisentan: a review of its use in pulmonary arterial hypertension

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

(2016) John Gerry Coghlan et al.   ANNALS OF THE RHEUMATIC DISEASES

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study

(2016) Marius M Hoeper et al.   Lancet Respiratory Medicine

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension

(2015) Paul M. Hassoun et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review

(2015) Andrew J. Peacock et al.   CURRENT MEDICAL RESEARCH AND OPINION

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

(2015) Vallerie McLaughlin et al.   EUROPEAN RESPIRATORY JOURNAL

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

(2015) Nazzareno Galiè et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension

(2014) Yugang Zhuang et al.   HYPERTENSION RESEARCH

Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials

(2014) K. M. Chin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes

(2014) Eve-Irene Lepist et al.   PLoS One

Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)

(2013) Bradley A. Maron et al.   AMERICAN JOURNAL OF CARDIOLOGY

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

(2013) Ganesh Raghu   ANNALS OF INTERNAL MEDICINE

The Fifth World Symposium on Pulmonary Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2013) Gerald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan

(2012) Shelley Shapiro et al.   AMERICAN JOURNAL OF CARDIOLOGY

Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension

(2012) Ori Ben-Yehuda et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

An update on the use of ambrisentan in pulmonary arterial hypertension

(2012) Michele D’Alto   Therapeutic Advances in Respiratory Disease

Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension

(2011) James R. Klinger et al.   AMERICAN JOURNAL OF CARDIOLOGY

Ambrisentan

(2011) James E. Frampton   American Journal of Cardiovascular Drugs

ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension

(2011) David B. Badesch et al.   Cardiovascular Therapeutics

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

(2011) Dermot S O'Callaghan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Overview of Current Therapeutic Approaches for Pulmonary Hypertension

(2011) Jason A. Stamm et al.   Pulmonary Circulation

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.

(2010) J. Craig Hartman et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension

(2010) Rodrigo Cartin-Ceba et al.   CHEST

Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension

(2010) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Tadalafil Therapy for Pulmonary Arterial Hypertension

(2009) Nazzareno Galiè et al.   CIRCULATION

Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension

(2009) Shannon E. Blalock et al.   JOURNAL OF CARDIAC FAILURE

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers

(2009) Rebecca Spence et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

(2009) Ronald J. Oudiz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

(2008) Michael D. McGoon et al.   CHEST

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Ambrisentan

(2008) Jamie D Croxtall et al.   DRUGS

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

(2008) N Galiè et al.   LANCET